CLEVELAND, Oct. 14, 2020 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that the Louis Stokes Cleveland
VA Medical Center in Cleveland,
Ohio has purchased the MRIdian® Linac MRI-Guided
Therapy System, a cutting-edge radiation therapy device that
combines the latest innovations in precision radiation delivery and
ground-breaking MR-guidance.
MRIdian offers advantages for the delivery of safe and effective
radiotherapy, including the ability to see the tumor and
surrounding tissue during treatment, adapt the therapy in response
to changes in patient anatomy and tumor size during treatment,
continuous tracking of the tumor during treatment, and automatic
pausing of the radiation if the tumor moves outside of the
boundary. As a result, the system delivers ablative, high-dose
radiation to the tumor while protecting the surrounding healthy
tissue from damage.
The ability to deliver high-dose radiation treatments, referred
to as stereotactic body radiation therapy (SBRT), means patients
can receive their treatment in fewer sessions than conventional
radiation therapy. Instead of 25 to 40 treatment sessions, patients
receiving SBRT may complete treatment in as few as one to five
treatment sessions. This is particularly beneficial for patients
who may have to travel a long distance for treatment.
The Louis Stokes Cleveland VA Medical Center is part of the VA
Northeast Ohio Healthcare System, which provides comprehensive,
seamless health care and social services for 112,589 Veterans
across Northeast Ohio. The VA
Northeast Ohio Healthcare System focuses on treating the whole
Veteran through health promotion and disease prevention. VA
Northeast Ohio Healthcare System contributes to the future of
medicine through education, training, and research
programs.
"We're proud to support the Louis Stokes Cleveland VA Medical
Center in their mission to offer the most advanced technologies to
Veterans," said Paul Ziegler, Senior
Vice President of Sales and Marketing at ViewRay. "Their investment
in a MRIdian program furthers their commitment to delivering the
highest quality health care to our nation's heroes."
Currently 39 MRIdian systems are installed at hospitals around
the world, where they are used to treat a wide variety of solid
tumors and are the focus of numerous ongoing research efforts.
MRIdian has been the subject of hundreds of peer-reviewed
publications, scientific meeting abstracts and presentations. More
than 10,000 patients have been treated with MRIdian. For a list of
treatment centers, please visit:
https://viewray.com/find-mridian-mri-guided-radiation-therapy.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs,
manufactures and markets the MRIdian® radiation therapy
system. MRIdian is built upon a proprietary high-definition MR
imaging system designed from the ground up to address the unique
challenges and clinical workflow for advanced radiation oncology.
Unlike MR systems used in diagnostic radiology, MRIdian's
high-definition MR was purpose built to address specific
challenges, including beam distortion, skin toxicity, and other
concerns that potentially may arise when high magnetic fields
interact with radiation beams. ViewRay and MRIdian are registered
trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Private Securities Litigation Reform Act. Statements in this press
release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other
things, the rate of new orders, upgrades, and installations,
ViewRay's anticipated future operating and financial performance,
and ViewRay's conference calls to discuss its quarterly results.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to commercialize MRIdian Linac
System, demand for ViewRay's products, the ability to convert
backlog into revenue, the timing of delivery of ViewRay's products,
the timing, length, and severity of the recent COVID-19
(coronavirus) pandemic, including its impacts across our businesses
on demand, operations and our global supply chains, the results and
other uncertainties associated with clinical trials, the ability to
raise the additional funding needed to continue to pursue ViewRay's
business and product development plans, the inherent uncertainties
associated with developing new products or technologies,
competition in the industry in which ViewRay operates, and overall
market conditions. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to ViewRay's business in general, see ViewRay's current
and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2019 and its
Quarterly Reports on Form 10-Q, as updated periodically with the
company's other filings with the SEC. These forward-looking
statements are made as of the date of this press release, and
ViewRay assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements,
except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/louis-stokes-cleveland-va-medical-center-purchases-viewrays-mridian-linac-for-mri-guided-radiation-therapy-301151927.html
SOURCE ViewRay, Inc.